Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lanreotide Acetate

FDA-approved product (solution, subcutaneous), marketed as Lanreotide Acetate, Somatuline Depot.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Lanreotide Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acromegaly
  • Carcinoid syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Somatostatin and analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA68.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae50.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lanreotide Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lanreotide Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Circulating Tumor Cells and Tumor DNA in HCC and NET

    NCT02973204 · start 2016-11

    Registered record
    Registry ID
    NCT02973204
    Conditions
    Carcinoma, Hepatocellular; Neuroendocrine Tumors
    Interventions
    Sorafenib; Radiofrequency ablation (RFA) or surgery; Everolimus; Lanreotide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-11
    Completion
    2020-01-08
    Enrolment
    167

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Hepatocellular; Neuroendocrine Tumors
    InterventionSorafenib; Radiofrequency ablation (RFA) or surgery; Everolimus; Lanreotide
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.

    NCT02698410 · start 2016-07

    Registered record
    Registry ID
    NCT02698410
    Conditions
    Neuroendocrine Tumours
    Interventions
    Lanreotide (Autogel formulation) and Temozolomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-07
    Completion
    2019-06-18
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroendocrine Tumours
    InterventionLanreotide (Autogel formulation) and Temozolomide
    PhasePhase 2
    Registry statusCompleted

  • Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects

    NCT02807233 · start 2016-07

    Registered record
    Registry ID
    NCT02807233
    Conditions
    Acromegaly
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-07
    Completion
    2017-09
    Enrolment
    115

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

    NCT02795858 · start 2016-06-14

    Registered record
    Registry ID
    NCT02795858
    Conditions
    Carcinoid Tumors
    Interventions
    Ramucirumab; Somatostatin Analog
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-06-14
    Completion
    2023-12-31
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoid Tumors
    InterventionRamucirumab; Somatostatin Analog
    PhasePhase 2
    Registry statusCompleted

  • A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours

    NCT02788578 · start 2016-06

    Registered record
    Registry ID
    NCT02788578
    Conditions
    Neuroendocrine Tumours
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2016-06
    Completion
    2017-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroendocrine Tumours
    InterventionNot recorded
    PhaseNot recorded
    Registry statusTerminated

  • The MetNET-2 Trial

    NCT02823691 · start 2016-04

    Registered record
    Registry ID
    NCT02823691
    Conditions
    Neuroendocrine Tumors
    Interventions
    Lanreotide and Metformin
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2016-04
    Completion
    2021-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroendocrine Tumors
    InterventionLanreotide and Metformin
    PhaseEarly phase 1
    Registry statusUnknown

  • Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

    NCT02685709 · start 2016-02

    Registered record
    Registry ID
    NCT02685709
    Conditions
    Acromegaly
    Interventions
    Octreotide capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-02
    Completion
    2021-08
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionOctreotide capsules
    PhasePhase 3
    Registry statusCompleted

  • Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg

    NCT02698384 · start 2016-01

    Registered record
    Registry ID
    NCT02698384
    Conditions
    Acromegaly
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2016-01
    Completion
    2016-06
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionNot recorded
    PhaseNot recorded
    Registry statusTerminated

  • Community-based Neuroendocrine Tumor (NET) Research Study

    NCT02730104 · start 2015-11-23

    Registered record
    Registry ID
    NCT02730104
    Conditions
    Gastroenteropancreatic Neuroendocrine Tumors
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-11-23
    Completion
    2020-05-13
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroenteropancreatic Neuroendocrine Tumors
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Pasireotide LAR and Pegvisomant Study in Acromegaly

    NCT02668172 · start 2015-08

    Registered record
    Registry ID
    NCT02668172
    Conditions
    Acromegaly
    Interventions
    Pasireotide LAR 60 mg; Pegvisomant
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-08
    Completion
    2017-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionPasireotide LAR 60 mg; Pegvisomant
    PhasePhase 4
    Registry statusUnknown

  • Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues

    NCT02351128 · start 2015-04

    Registered record
    Registry ID
    NCT02351128
    Conditions
    Carcinoma, Merkel Cell
    Interventions
    Lanreotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-04
    Completion
    2017-05-15
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Merkel Cell
    InterventionLanreotide
    PhasePhase 2
    Registry statusCompleted

  • Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.

    NCT02396966 · start 2014-12

    Registered record
    Registry ID
    NCT02396966
    Conditions
    Acromegaly
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-12
    Completion
    2018-05
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Lanreotide In Polycystic Kidney Disease Study

    NCT02127437 · start 2014-09-19

    Registered record
    Registry ID
    NCT02127437
    Conditions
    Autosomal Dominant Polycystic Kidney Disease (ADPKD
    Interventions
    Lanreotide; saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-09-19
    Completion
    2019-07-31
    Enrolment
    159

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutosomal Dominant Polycystic Kidney Disease (ADPKD
    InterventionLanreotide; saline
    PhasePhase 3
    Registry statusCompleted

  • Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients

    NCT02075606 · start 2014-05

    Registered record
    Registry ID
    NCT02075606
    Conditions
    NeuroEndocrine Tumours
    Interventions
    lanreotide acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-05
    Completion
    2017-06
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroEndocrine Tumours
    Interventionlanreotide acetate
    PhasePhase 4
    Registry statusCompleted

  • Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy

    NCT02054637 · start 2014-04

    Registered record
    Registry ID
    NCT02054637
    Conditions
    Acid Reflux Esophagitis; Non-acid Reflux Esophagitis
    Interventions
    Lanreotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2014-04
    Completion
    2016-04
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcid Reflux Esophagitis; Non-acid Reflux Esophagitis
    InterventionLanreotide
    PhasePhase 2
    Registry statusUnknown